if i was bta management, page-6

My understanding is that GSK is one of very few global companies that can produce and market Lani, so its almost a done deal with them, the royalty will be a healthy 20% or 10% each for Biota and DS which should put a rocket up the share price.

The disadvantage is that GSK will produce both Relenza and Lani and should Lani be fast tracked for the ROW than it will shorten Relenza's profitability for its remaining patent life.

If DS and Biota decided to set up a joint Lani manufacturing company with a plant in say Japan and Australia (government grants would be possible) then in my humble opinion the share price would go off the Richter scale.